It is noteworthy that activating mutations in the RAS and RAF genes are found in more than 90% of PDAC [91,92,93] and 70% of PTC cases [94], respectively, whereas such mutations are rarely detected in HCC and ccRCC. This evidence concerns the gene RAF1 and hepatocellular carcinoma.